Drugs / NGM831
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05215574 | Mar 2022 → Jul 2025 overdue | bladder transitional cell carcinoma, breast cancer, cholangiocarcinoma, colorectal carcinoma +11 | NGM Biopharmaceuticals, Inc | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-31 | NGM Biopharmaceuticals, Inc | NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors ngmbio.com ↗ |
| 2021-08-23 | NGM Biopharmaceuticals, Inc | NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research ngmbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGM831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215574 ↗ |
| Route | Intravenous | “NGM831 is given intravenously (IV)” NCT05215574 ↗ |